# A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

> **NCT06516965** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 346 (actual)

## Conditions studied

- Prurigo Nodularis

## Interventions

- **DRUG:** Povorcitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06516965
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2026-10-19
- **Final completion:** 2027-05-03
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516965, "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06516965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*